Sarepta's Duchenne gene therapy slows disease progression at three years

By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease progression and showed sustained benefit in patients' ability to control and ...
Yahoo

Second patient death reported with gene therapy for muscular dystrophy

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the ...
The American Spectator

Muscular Dystrophy Therapy Falls Short. Or Did It?

It wasn’t the best of news for sufferers of Duchenne muscular dystrophy (DMD). But neither was it dismal. It does appear that the first FDA-approved gene therapy, called Elevidys, can, with a one-time ...
KETV Omaha

First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids

Muscular dystrophy is *** debilitating condition affecting one's ability to move around the world. There is currently no cure for the disease which is why some are now turning to technology to live ** ...
WCVB Channel 5 Boston

First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids

The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's ability to help ...